Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination formulation** consisting of live attenuated **yellow fever virus strain 17D-204 live antigen** together with its accompanying **sodium chloride diluent** used for reconstitution prior to administration. It corresponds to the YF-VAX presentation supplied as a lyophilized live-virus vaccine plus preservative-free sterile sodium chloride injection. The biologically active component is the 17D-204 yellow fever vaccine virus, a live attenuated flavivirus antigen developed by **Sanofi Pasteur** to prevent **yellow fever**. After administration, the vaccine induces humoral and cellular immune responses, with protective activity primarily associated with generation of neutralizing antibodies against yellow fever viral envelope antigens. The sodium chloride component functions as a reconstitution diluent rather than as a therapeutic active ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride + yellow fever virus strain 17d-204 live antigen.